Expect Caplyta and Secuado to Continue on Admission

April 2020

Patients may come in on new atypical antipsychotics...Caplyta (kah-PLY-tah, lumateperone) or Secuado (seh-KWAH-doh, asenapine).

Caplyta is a 42 mg oral capsule that's taken once daily.

Expect it to be saved for patients with schizophrenia who don't respond to or can't tolerate lower-cost atypicals, such as olanzapine or risperidone.

Get unlimited access through an Enterprise license

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Storage & Disposal Tackle Issues With Meds Kept in Original Containers
Antibiotics Consider Fetroja a "Salvage Therapy" for Resistant Infections
Med Safety Avoid Ambiguous Abbreviations
Cholesterol Nexletol Will Be a New Add-On Med for High Cholesterol
Practice Know Where to Find Info on Med Handling, Prep, and Storage
Neurology & Pain Prevent Mishaps With Low-Dose Naltrexone
Antipsychotics Expect Caplyta and Secuado to Continue on Admission
Inventory Management Use Strategies to Minimize Pharmacy Shrink
NSAIDs Anticipate an OTC Version of Voltaren Gel